Sanofi SG&A Expenses 2012-2026 | SNY
Sanofi annual/quarterly sg&a expenses history and growth rate from 2012 to 2026. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Sanofi sg&a expenses for the quarter ending March 31, 2026 were $2.724B, a 16.35% increase year-over-year.
- Sanofi sg&a expenses for the twelve months ending March 31, 2026 were $11.180B, a 18.31% increase year-over-year.
- Sanofi annual sg&a expenses for 2025 were $10.797B, a 8.65% increase from 2024.
- Sanofi annual sg&a expenses for 2024 were $9.937B, a 14.13% decline from 2023.
- Sanofi annual sg&a expenses for 2023 were $11.572B, a 4.68% increase from 2022.
|
Sanofi Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025 | $10,797 |
| 2024 | $9,937 |
| 2023 | $11,572 |
| 2022 | $11,054 |
| 2021 | $11,305 |
| 2020 | $10,726 |
| 2019 | $11,069 |
| 2018 | $11,643 |
| 2017 | $11,369 |
| 2016 | $10,497 |
| 2015 | $10,418 |
| 2014 | $12,106 |
| 2013 | $11,426 |
| 2012 | $11,507 |
| 2011 | $11,883 |
|
Sanofi Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $2,724 |
| 2025-12-31 | $3,185 |
| 2025-09-30 | $2,678 |
| 2025-06-30 | $2,593 |
| 2025-03-31 | $2,341 |
| 2024-12-31 | $1,301 |
| 2024-09-30 | $2,948 |
| 2024-06-30 | $2,859 |
| 2024-03-31 | $2,828 |
| 2023-12-31 | $3,159 |
| 2023-09-30 | $2,807 |
| 2023-06-30 | $2,808 |
| 2023-03-31 | $2,798 |
| 2022-12-31 | $2,982 |
| 2022-09-30 | $2,663 |
| 2022-06-30 | $2,739 |
| 2022-03-31 | $2,670 |
| 2021-09-30 | $2,673 |
| 2021-06-30 | |
| 2021-03-31 | $2,645 |
| 2020-09-30 | $2,551 |
| 2020-03-31 | $2,584 |
| 2019-09-30 | $2,570 |
| 2019-03-31 | $2,699 |
| 2018-03-31 | $2,842 |
| 2017-12-31 | $3,183 |
| 2017-09-30 | $2,720 |
| 2017-06-30 | $2,825 |
| 2017-03-31 | $2,641 |
| 2016-12-31 | $2,811 |
| 2016-09-30 | $2,538 |
| 2016-06-30 | $2,708 |
| 2016-03-31 | $2,440 |
| 2015-09-30 | $2,738 |
| 2015-06-30 | $2,929 |
| 2014-06-30 | $3,093 |
| 2013-06-30 | $3,015 |
| 2012-06-30 | $2,942 |
| 2012-03-31 | $2,588 |
| 2011-12-31 | $3,073 |
| 2011-09-30 | $2,937 |
| 2011-06-30 | $3,253 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |